-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RzRBuTsU2Opt46P+H+464tjFdIKuj3aU/xFqq4wdBukq8zYYVWzjwCnUKTNgYYll
 9W22LjUTqd6xuAlGb7vXAA==

<SEC-DOCUMENT>0000950123-09-056882.txt : 20091103
<SEC-HEADER>0000950123-09-056882.hdr.sgml : 20091103
<ACCEPTANCE-DATETIME>20091103161158
ACCESSION NUMBER:		0000950123-09-056882
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20091103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091103
DATE AS OF CHANGE:		20091103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		091154621

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c91897e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): November 3, 2009</B>


<P style="font-size: 24pt" align="center"><B>CYCLACEL PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-50626</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>91-1707622</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>200 Connell Drive, Suite 1500<BR>
Berkeley Heights, New Jersey<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07922</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(908) 517-7330</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;2.02</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify"><B>Results of Operations and Financial
Condition.</B></DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt; text-indent: 4%" align="justify">The information set
forth under this &#8220;Item&nbsp;2.02. Results of Operations and Financial
Condition,&#8221; including the exhibit attached hereto, shall not be deemed
&#8220;filed&#8221; for purposes of Section&nbsp;18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by reference into
any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.

<P style="font-size: 10pt; text-indent: 4%" align="justify">Attached as
Exhibit&nbsp;99.1 is a copy of a press release of Cyclacel Pharmaceuticals,
Inc., dated November&nbsp;3, 2009, announcing certain financial results for the
quarter ended September&nbsp;30, 2009.

<P style="font-size: 10pt; text-indent: 4%" align="justify">The Company will
conduct a conference call to review its financial results on Tuesday,
November&nbsp;3, 2009, at 4:30 p.m., Eastern Time.

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;9.01</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify"><B>Financial Statements and Exhibits</B></DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%">(d)</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The following exhibit is furnished with this
Report:</DIV>
</TD>
 </TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="15%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="80%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exhibit&nbsp;No.</U></B></DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left"><B><U>Description</U></B></TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV
style="margin-left: 0px; text-indent: 0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1
</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated November&nbsp;3, 2009</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="justify">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<P style="font-size: 10pt" align="center"><B>CYCLACEL PHARMACEUTICALS, INC.</B>

<P style="font-size: 10pt; margin-left: 46%" align="justify">By: <U>/s/
Paul
McBarron&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Name:
Paul McBarron<BR>
Title: Executive Vice President &#8212; Finance,<BR>
Chief
Financial Officer and Chief<BR>
Operating Officer&nbsp;<BR>


<P style="font-size: 10pt" align="justify">Date: November&nbsp;3, 2009

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">3
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="15%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="80%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exhibit&nbsp;No.</U></B></DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left"><B><U>Description</U></B></TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV
style="margin-left: 0px; text-indent: 0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1
</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated November&nbsp;3, 2009</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c91897exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c91897p9189701.jpg" alt="(CYCLACEL PHARMACEUTICALS LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2009<BR>
FINANCIAL RESULTS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>&#151; Conference Call Scheduled Tuesday, November 3 at 4:30 p.m. Eastern &#151;</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Berkeley Heights, NJ, November&nbsp;3, 2009 </B>&#151; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:
CYCCP; &#147;Cyclacel&#148; or the &#147;Company&#148;) announced today financial and operating results for the third
quarter of 2009. The Company&#146;s net loss for the quarter was $3.1&nbsp;million or $0.13 per share. This
compared to a net loss of $17.6&nbsp;million or $0.86 loss per share for the same period in 2008. As of
September&nbsp;30, 2009, the Company had $14.4&nbsp;million in cash and cash equivalents.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;Our recent achievement of 30% one-year survival in two of the three randomized schedules of the
Phase 2 study of sapacitabine as a treatment for elderly patients aged 70 and older with acute
myeloid leukemia (AML)&nbsp;provides a strong rationale supporting the continued development of this
novel agent,&#148; said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. &#147;We are
working with the FDA to design a registration study for sapacitabine in hematological malignancies.
We continue to concentrate our efforts on advancing sapacitabine into Phase 3 development for AML
and/or myelodysplastic syndromes (MDS)&nbsp;while preserving cash for the next twelve months. We are
also looking forward to reporting in 2010 data from our ongoing Phase 2 studies of sapacitabine and
seliciclib in lung cancer.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Recent Highlights:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Reported 30% one-year survival from the Phase 2 sapacitabine trial in elderly patients with
AML aged 70 and older in two out of three randomized schedules;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Type A meeting granted by the FDA in the 4th quarter of 2009 to discuss the design of Phase
3 registration studies in AML and/or MDS;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Phase 3 study designs to be included in an upcoming submission requesting a Special
Protocol Assessment or SPA;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Raised $3.4&nbsp;million in gross proceeds in a registered direct offering in July.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Key Financials:
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Total revenues for the third quarter of 2009 were $0.2&nbsp;million representing a decrease of 14%
compared to $0.3&nbsp;million for the same period in 2008. These revenues were mainly attributable to
sales of the Xclair<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> products.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Total research and development (R&#038;D) expenses in the third quarter of 2009 were $1.4&nbsp;million, a 65%
decrease as compared to $4.0&nbsp;million in the third quarter of 2008. $1.6&nbsp;million of the overall
decrease was associated with the discontinuation of the Company&#146;s preclinical programs from the
cost-containment measures implemented in September&nbsp;2008 and June&nbsp;2009. The Company recognized cost
reductions of approximately $1.0&nbsp;million in the third quarter 2009 as compared to the same period
in 2008 due to the completion of patient enrollment in the APPRAISE trial in the third quarter of
2008.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Total selling, general and administrative expenses (SG&#038;A) for the third quarter of 2009 were $2.2
million, a 32% decrease as compared to $3.2&nbsp;million in the third quarter of 2008. The reduction in
operating expenses in the third quarter of 2009 compared to the same period in 2008 is primarily
attributable to the cost-containment measures implemented in September&nbsp;2008 and June&nbsp;2009 and the
concentration of the Company&#146;s resources on the clinical development of sapacitabine.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Other operating expenses in the third quarter of 2008 also included a non-cash charge of $6.8
million for goodwill and intangibles impairment in respect of the acquisitions of Xcyte Therapies,
Inc. and ALIGN following Cyclacel&#146;s annual test for impairment and restructuring costs.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Other income (expense)&nbsp;showed income of $0.2&nbsp;million in the third quarter of 2009 as compared to
expense of $4.1&nbsp;million in the third quarter of 2008. The decrease in expense was primarily due to
an unrealized foreign exchange loss of $4.8&nbsp;million in the third quarter of 2008 compared to a $0.1
million foreign exchange gain in the same period in 2009 arising from intercompany loans with our
wholly-owned subsidiaries due to the translation effects of the US dollar against the British pound
together with a change in the valuation of warrants and a reduction in interest income earned.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The net loss in the third quarter of 2009 was $3.1&nbsp;million or $0.13 per share as compared to $17.6
million in the third quarter of 2008 or $0.86 per share.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel also reported results of its operations for the nine months ended September&nbsp;30, 2009.
Total revenues for the nine months ended September&nbsp;30, 2009 were $0.7&nbsp;million representing an
increase of 16% compared to $0.6&nbsp;million for the same period in 2008. These revenues were mainly
attributable to sales of the Xclair<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> products.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the nine months ended September&nbsp;30, 2009, R&#038;D expenses were $7.2&nbsp;million, a 54% decrease as
compared to $15.7&nbsp;million in the comparable period in 2008.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the nine months ended September&nbsp;30, 2009, SG&#038;A expenses were $6.7&nbsp;million, a 41% decrease as
compared to $11.3&nbsp;million in the comparable period in 2008.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The reduction in operating expenses in 2009 compared to 2008 is primarily attributable to the
cost-containment measures implemented in September&nbsp;2008 and June&nbsp;2009 and the concentration of the
Company&#146;s resources on the clinical development of sapacitabine.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Other operating expenses for the nine months ended September&nbsp;30 2008 also included a non-cash
charge of $6.8&nbsp;million for goodwill and intangibles impairment in respect of the acquisitions of
Xcyte and ALIGN and restructuring costs. For the nine months ended September&nbsp;30, 2009, the Company
recorded restructuring costs of $0.4&nbsp;million.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Other income (expense)&nbsp;for the nine months ended September&nbsp;30, 2009 showed an expense of $2.0
million as compared to $0.4&nbsp;million for the same period in 2008. The 2009 loss included a
non-operating expense of $1.7&nbsp;million related to payments due under an agreement with Scottish
Enterprise as a consequence of the headcount reductions implemented by the Company. During 2008,
the Company recorded a charge of $3.3&nbsp;million associated with the warrant derivative as compared to
income of $0.2&nbsp;million in 2009 as a result of the Company&#146;s common stock price at each quarter end.
The decrease in expense was primarily due to unrealized foreign exchange loss of $4.6&nbsp;million in
the nine months ended September&nbsp;30, 2008 compared to $0.1&nbsp;million foreign exchange loss in the same
period in 2009 arising mostly from intercompany loans with our wholly-owned subsidiaries due to the
translation effects of the US dollar against the British pound.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the nine months ended September&nbsp;30, 2009, the Company reported a net loss of $15.2&nbsp;million or
$0.71 per share, compared to a net loss for the same period in 2008 of $32.4&nbsp;million or $1.59 per
share.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Conference call and Webcast Information:
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel management will conduct a conference call on November&nbsp;3, 2009 at 4:30 p.m. Eastern Time to
review the quarterly results. Conference call and webcast details are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Conference call information:<BR>
US/Canada call: (877)&nbsp;493-9121/ international call: (973)&nbsp;582-2750<BR>
US/Canada archive: (800)&nbsp;642-1687 / international archive: (706)&nbsp;645-9291<BR>
Code for live and archived conference call is 37927625

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel
website at <U>www.cyclacel.com</U>. The webcast will be archived for 90&nbsp;days and the audio replay for 7
days.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and
commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious
disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the
treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and
in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor,
is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and
VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel&#146;s ALIGN Pharmaceuticals
subsidiary markets directly in the U.S. Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for radiation dermatitis, Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid
and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges for xerostomia. Cyclacel&#146;s strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial
products and a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U>
for additional information.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Risk factors</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety, and intended
utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials,
plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk
that product candidates that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel
will not obtain approval to market its products, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated with reliance on collaborative
partners for further clinical trials, development and commercialization of product candidates. You
are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable
words to be uncertain and forward-looking. These factors and others are more fully discussed under
&#147;Risk Factors&#148; in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2008, as
supplemented by the interim quarterly reports, filed with the SEC.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Investors/Media:<BR>
Corey Sohmer, (908)&nbsp;517-7330<BR>
<U>csohmer@cyclacel.com</U>

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> Copyright 2009 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and
Cyclacel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks
of Sinclair Pharma plc.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Period from</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>For the three</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>For the nine</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>August 13, 1996</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(inception) to</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2008</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2008</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="18"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Revenues:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Collaboration and research and
development revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Product revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">257</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">590</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">688</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,526</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,671</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">269</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">626</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,197</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Operating expenses:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of goods sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">163</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">315</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">472</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">901</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,030</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,394</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,174</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">167,587</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,188</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,703</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70,011</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Goodwill and intangibles impairment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,344</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,344</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,934</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">489</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">489</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">366</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,634</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total operating expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,201</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,745</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,715</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">249,067</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13,932</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,515</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(33,577</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13,991</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(240,870</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Costs associated with aborted 2004 IPO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,550</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payment under guarantee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,652</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,652</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of derivative </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(308</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">432</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">101</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,321</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(195</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,512</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Foreign exchange gains/(losses)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,776</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,638</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(129</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,172</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,184</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,635</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(69</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(41</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(244</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(156</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,613</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,126</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">186</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(377</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,038</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,852</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss before taxes</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(18,058</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,329</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(33,954</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,029</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(235,018</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">411</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">205</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,511</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">796</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,070</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(17,647</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,124</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(32,443</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15,233</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(217,948</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividends on Preferred Ordinary shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38,123</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss applicable to common
shareholders</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(17,647</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(3,124</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(32,443</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(15,233</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(256,071</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per share &#151; basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.86</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.13</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1.59</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.71</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,433,129</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,172,259</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,433,129</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,356,206</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">As of</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">As of</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">December 31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">September 30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,220</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,433</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">140</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,652</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,225</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property, plant and equipment (net)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,748</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,121</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deposits and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">195</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,542</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LIABILITIES AND STOCKHOLDERS&#146; EQUITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">754</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,463</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,186</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,228</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,615</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,336</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrants liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">238</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current portion of other accrued restructuring charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,029</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,063</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,627</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,328</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other accrued restructuring charges, net of current</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,062</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">267</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long term payables</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">626</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,315</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,595</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Preferred stock, $0.001 par value; 5,000,000 shares
authorized at December&nbsp;31, 2008 and September&nbsp;30,
2009, respectively; 2,046,813 shares issued and
outstanding at December&nbsp;31, 2008 and September&nbsp;30,
2009, respectively
Aggregate preference in liquidation of $20,673,000 at
December&nbsp;31, 2008 and September&nbsp;30, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock, $0.001 par value; 100,000,000 shares
authorized at December&nbsp;31, 2008 and September&nbsp;30,
2009; 20,433,129, and 24,433,129 shares issued and
outstanding at December&nbsp;31, 2008 and September&nbsp;30,
2009, respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Additional paid in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">223,377</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">225,864</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated other comprehensive loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit accumulated during the development stage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(202,715</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(217,948</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,642</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,947</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,542</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">SOURCE: Cyclacel Pharmaceuticals, Inc.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c91897p9189701.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c91897p9189701.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`(D"CP,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!"0`22``,DG@`#J2>PH#;R2/D7XG_
M`+8GP]\"7MSHOARVF\=:U:[DG?2[R"V\/6L^W/DR:WLG^U2JS+N%G;W"`AT:
M59$*#]+X?\,,ZS>E3Q6-G')\+4UBJL)2Q,HW^)4+PY$];>UG"3TDH.+3/R+B
MCQBX>R"M4P66TY9[C:5U)T*D882$K?"\3:?/)-KF5&G4BO>C*<9Q<3Y.U?\`
M;4^,VM7/D:!9^&]!$F8K6WTS1IM4OF9\;27U.YNDGG!SC9;1J0>4)&:_1L+X
M5<+8.GSXRKBL7R:RE5KQHTTEOI2C3<8OK>HWVDC\FQGC5QGC:GL\OHX/`*7N
MPA1P\J]6[VUK3JQE+MRTHKO%[G/3_M,?M.Z<HNK[Q#J=M;+B0F\\">&;:V*'
M.,RMX9C(0]B)`?>NZ'`7`%5^RHX*E*IM:&88J4D_\*Q35_\`MWY'GS\3/$["
MI5:^85J5):_O,KP<(6_Q?4HNWFI+U.P\-_MR_$W3)57Q%H?ACQ):;PSB*&ZT
M+42N4W1QW=M--;(NT/@M82$,^22!M/EX[PCR"M%_4<7BLOJ6LKRA7I7UU<)1
MA4>K6U:*LK63=SV,M\<N)L+)+,<#@LRHWN^6,\+6MI=*I"4Z25KVO0D[N]VE
MRGVQ\)/VE?AY\6;@Z3827?AWQ(D2R?V%KIM87O.563^Q[R&=HM2V.ZCR\0W!
M&7$&Q69?RGB3@/.^&8?6:L88W`7:^L8?G:I[M>V@XJ5*Z3][WJ:=H^TYFD_V
MSA+Q*X>XLJ?5,/*>6YE&*?U7%<D74O9/ZO4C)PK<K:]WW*K5Y>RY4VOH6OBC
M]""@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`:[I&C
MR2.L<<:L[N[!41%!9G=F("J%!)).`!32;:C%-MNR2U;;V27<3:BG*348Q3;;
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MADXX>C9JTZW-.#G"4O=C.O%1G'GY,+4E!R3;'XU_'OQVL&E_`WX:6G@706G:
M)3X.\*V<UJ1MEBC@U+Q#J>G)I%DD:1E5D2"P8/&PWX(175X4X.R9SK\6Y]/-
ML8HIVQN+G&:V;E2PU*J\3-R;NXN=9<K7N_::H<:\>YZJ>%X%X9IY#@.9Q3R_
M`TY0VE%1K8NM1C@Z:BE:,HPP\E)/WK6BK%[IW[=>AP2:M/)XMFCM,SM%9:IX
M/U^9MH+%4T73KN\EO._[I+63/`"\@5%&OX0XJ:PT(X.FY^ZG.EC<-%7TUKU(
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M2/+[*KB(R?.JG.ZE.,IJ,JM*%.K)2<_:U/K&OC#]`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#XO\`VQ/BAJ7AWP[I7PQ\,+*_B#XA
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MQ_&/$?-&-2$%^[FHQBE%>]*5#"SJ15*%KXFO-R<81;C3\Y/@_P`.?`IK'Q%\
M7=+D^+?QM\:D7OA[P2))-7L]-N))T2.]UZXE,KZK?2W++"NVVNU::"2&U241
MM=Q^VLSQW%RJX'AG$+AGA/*?W>)QUE0G4BHMN&'C'E5&G&%Y.]2FU"49U7%R
M5&7SG]CY;P(Z&8<785\6\;9U^\PF6W>(IT9N22J8J4N9UZLYM05J55.I&5.A
M&:BZ\=CQUH/Q2N;5-:^/'QVTSX2:;>H)M+\">&VOM0NX+5V_=6D/A3PW>6PN
M8+?`@%R]QJ31[3YT^22W-E&,X>I5'A.#^#ZO$=>B[5<?B53I0<UO.6+Q,)\D
MI_&X*%!2O[E/9+LSW`<4U*4<;QYQW1X1PU9<U#*\&ZM6I&#>E..!P=2ESQI_
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MU;*\RP,9X;#5:/L:_LL7&E7IK%N-25.4J4;:4XJ,JEIKD4>67@OQO_90O_\`
M@IY!\&OVJOA=XZ@^'OAOQ#X&?PEK'A;Q[I]_>ZCH9\*^,O%UGJ%[H@T>>:VO
MW?5Y-0@^SO)I\<T5I#=^<KW3P1?EA^T'[8>'-''A[P]H6@+=W%^NAZ-I>CK?
M79!NKT:99060N[D@D&XF$'F.<_><T`;-`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`'PWH.@1_$[]K[QGXDU$R2:/\(++1['3+:10\9U<
MV;1622!MZQPPZI+X@U&+RS&WG6UNQ'^L!_6\9C'P_P"&>58##VAB>)JE>I5D
MG9JCSIU&K6;E*DL/0G=-<DYK^5GX;@,OCQ-XOYUF6(O+!\'T\/2HP:NOK#IN
M--.]THPKRQ>(ARN+]I"F[?&G5T#4-'\??%[XL_'3Q+;-/X3^!UC=:+X3LY9#
M*KWWAZ'4+N^U>&+.QI]UO>7-O&R95]9M&`,]JKC3&4,5DO#/#?".`FJ>8\6U
M(5\9-+EM3Q,J<*=&3W4;2A"K)/6-"HKJG4:,\OQ&#S[B_BSCK,J;J93P/2J8
M;`4Y.Z=7"1JU*N(C'X>:\:E2C%QNI8BD[.K24C#\,+XI\-:?IWCS5K"WUWX_
M_M"ZA-!X`_M-H)8?`OAQ[);B/4F:1)6LK.QTN\@NY8+>(E819VTB(8YT/7F'
M]GXVM7R?#5I8+@S@FG&68^R4HRQ^)53E=)).*G.M5A*G"<Y6<_:U8RDI4VN'
M*UFF6X?#Y]BZ$,?Q_P"(564<J]LXRCEF#=-359MJ3ITZ%"I&K.G3A=4_8T9Q
MBXU8O9\#?#];G4==B\":+X9^)GB;3-5FM?%_QM^+L=WJNF/XDC\K[9I7@K18
MDN)KXV!8E[K[3;('<H;F9&C`Y<WSETJ&#>;XK%9!@*]&,\%D63.%&JL*[\E;
M'5VX0I^V^S3]G4DXI2]E3DI-]F1\/JIB<='(<%@N)<SPM>4,PXDS]5*]%XQ6
M]I0RW#152=1T+^]5]K2CS-Q]M4BX)=M>_"+XS6D-Q)=ZM\'OBC9R0@R^%?%G
MPVTKP[:A58/)9Z5J.B6[/%.4&V&>\+H'",ZJ`6'DT>)>%IRA&EALZX>JQE[N
M+P>9UL3.[T4ZU*O))QOK.%*S<;J+;LCVZW"/&=&%1UL7P_Q11E'WL#C\GH82
M%D[NG0K8:#<96TISK<T5+E<DE=GG.B>';?X3>'/&GQXT;P7\4M"T71]#UR3Q
M1^S38Z2/$5]XIOM/A^P^?H7]H7:OJ.C)-="\BF:T9P(;@P2"T(MI;XKXFG/!
MPR?$UL%G^,P_LJV$SS#2]E7I4I24W3E3IQM"NTN2K%5;*+BYPE77.HX)X0IT
M,=//L'0S#A;`8E5J&.X<Q</:X>K6C%T_:PJU9WGAN:7M*,G1YI24E3J1P\O9
MO;^&G[.OQ!OOC+\4_BI\4/B?K/Q"^"/Q?\(6\6@_LY_$/2KR]T3P6=6N_#NN
M6MAJOA35]3OM!L;G0K?3[W3%AM+',IU.XEF994;S_P`S;;;;=V]V?KZ2222L
MEHDM$DMK(^T]%T31O#6DZ?H/AW2-,T#0](M8K'2M%T6PM=*TG2[*!=D%GI^G
M6,45O96L:85(H8T11P`!2'MY6-.@#`M_%?A:ZU-]%M/$F@7.L1%Q)I-OK&G3
M:G&4>1'#V$5R9T*O%*IR@P8W!Y4X`+UAJ^DZFUTFF:IIVH/8S?9[U+"]MKMK
M.<%AY-TMO*QMYLHXV2;3\C<<&@!=2U?2M%@2YU?4]/TFVDF6WCN-2O;:P@>X
M=))%@26ZE16F:.*5@@)8B-B!A3@`M7%Q;V<$MU=3PVMM;QM+/<7$J0001(-S
MR2RR,J1QJN268@`=30!DZ1XF\-Z^TZ:#X@T/6FM21<KI&K6&HM;$2-$PG6SN
M)#"1*CH=V/F0CJ#0!H6>H6&H"X.GWUG>BSNIK&[-G<PW(M;ZWV^?9W!A=O(N
MH]Z;XGVNN]=P&10!<H`S1K&D?VD=&&JZ;_:XB\\Z2+ZU_M(0[0_G&Q\WSA%L
M(;=LQ@YSB@#2H`R-7U_0?#T*7&O:WI&AV\CB.*?5]2L],A>1ND:2WDT:LY_N
M@DT`/.MZ,FF?VTVKZ8NC;%D_M8W]HNF>6\HA5_MYE\C8TS",'?@L0O4XH`R8
M_'7@B61(HO&/A6261UCCCC\0Z0\CR.0J(B+>$L[,0``"23@4`;4FK:5#J,&C
MR:GI\6K7,)N;;2Y+RV34;BW7SMT\%DT@FEA'V>?+JA7]S)S\C8`*GB7^UQX<
MU_\`L`NNNC1-5_L4QK:M(-6^PS_V<8TO@;9G%YY)`N`8B<"0;,T`?//P^UWX
MV:AXVTO_`(D^CI\,Y]1\1C59M8D\8+K]AX)CT^\G^%U_91>*;A+^U\?WVH//
M;>*-)U2(S6$=CIQ:UM+FYE,H&WE8^H:`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/E']FZW7_A,/VD-
M0(4SW'QG\0V+R$?O3!INH:HUM$S=XXQ>R!%_AW-ZU^B\=3:RS@6@O=A3R3#5
M%'9*56G2YFET<N1<SZZ'Y1X;4U_;'B1B-/:3XBQ=)O[7+1JUW"+?:/M9<JZ7
M?<\5\`V<TO['_BQV#PW?B[QW$FJRQC,S#6O'/A;PYJ4K!@2'%BDBG)R`F<CJ
M/J\YJPAXFY;&-G3RS+VZ,7I%>PP&+Q5)*UM'4:>G5[,^*X?HSEX/YLVG"KFV
M:15=KXG]9S/`X.M)]4U236NME>ZW7T3XTMY;7Q9\3-7TZ06%]X;^"OAWP_X5
MGACC`T:]\6ZSXVBN-1M555:`Q2:1H)*1NH=+$+Q@8^'RJ<99;D.%K1]K1QV>
M8G$8N+;_`'T,'0P+C2EK:7,JV(UDG9U+ZZGZ+G5.=+-N)L9AI?5Z^6\.83"8
M&44E]7J8_$YE&=:"23CRRP^%=HM<T:5M-#WC0-"TOPQHNF>']%M(K'2](LH+
M&RMH8TB2.&!`H8K&JJTKMF21\9=W=VRS$GY#&8O$8[%8C&8JHZN(Q,Y5)RDV
MVY2=^K;LMHK:,4DM$C[S`8'"Y7@L+E^"I1P^%P=.-*G"*44HQ5MHI+FD[RD[
M7E)N3U;+5_/>6UNKV-C]OG^UZ?"UO]IBM-EK<W]M;W]YYLP*M]DL9;F[\H?-
M-]E\I,/(I',=9YSX&^&\VA7&E^*/'6L:=\0?BMIVD^)O##?$W_A%=,\)ZI-X
M.U[Q:_BBU\+)IFDSRV]MIUBEOH=KE79[EM$CNICY\\I8`]3H`*`/RK^/$^M_
MM=?M=_\`#'^G>,?%O@7X1_!GP5;?$#X[-X9OIM%U#XAZMXA'AJ[\.>!5O;>3
M>-&CT;7M-NFE.8F>\U19(#<V&GSQ@'U+;_L,?LB65G8V5G^S_P##NT_LVYM[
MRRO[;29+?7(+JU\LV\P\117"ZH[HT4;C?>,-X,A&]BQ`/EKXVV=C^P[^TM9_
MM7Z187<?P0^/4]KX`_:*TG37;R?#/C2ZNA>>%OBK!I:,JW"221:C'?84E&O=
M4DC\V[UR-*`_`VO!6L0?ML_M5I\0-/C%W^SE^R'KVK:)X0N9)X;[2/B=\>;B
MUA%WXIM+9(1&VF>%M/FM)]/N&DG82SZ;?VD@CU2XB@`.#^$WPUF_;O\`C%\8
M?C+\;=4U37OV>_`/Q&\0_"_X._`V?5M7MO"E[?>#H[33[_Q]XBTBTFMH+B>X
M,_VF..4SS->7UU#*Z6FDVD=T!^!]]>#/V6OV=_AQXKTGQQX`^#_@?P5XKT2S
MNK#3M:\+Z/%H=TEI?64FGWD5RNG-%%?^=:2NKO=QS,S$2%O,4.`-O*Q\V?\`
M!.__`)!7[8/_`&??^T#_`.DW@F@#[[UO6](\,Z+J_B/7]2L]&T'P_I>H:WK>
MKZC/':Z?I6D:7:2WVI:E?7,I"6UG;6<$TTLKD*B1,Q.!0!_/_J.F>(-#T(?\
M%8TM-:OM:O?VCD\3/X9ENC9W$'[+\LFH_!S2M)MHYOF_MV]M+G3E,LO^CM:R
MV4R0Q0P2&X`/U8_:N_:.@^$/[)GC#X[^![FWU*YU'PIH$WP[O=@DMKB_\?S:
M9I_AK6Q%(-LUO:0:S'JYA?`ECL&C/,@!`/,/@3^P/\.--\)Z;XH_:7\/Z;\>
M?CWXDB76?'_B_P")$LOC6&SU.]B#GPQH-KJTDMC%H6DK(UM"ZVV99!+,GE0-
M;VUH`<I^W!\'OAG\%/V!/VC?#GPK\':3X'T'6;SPKXGU'1]%%Q%I\FNW?C?X
M<:3<WT-K-/(ED9-/T73(C#;"*+_1MXC\R21G`//_`("6G_!,._\`"_P7L#!^
MSM<_%6]T'X<VAMBNG-XFN/B#<Z?HT/D%3^\;77\1OMP?F-PV.M`%KXJ_\IB/
MV:/^S;=>_P#1?[0%`'ZV4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!X!^U'XO\0>!?@-\0/$'A:_G
MT;7!;:'H5GX@MA;&?PK'XN\4:)X3OO&$8O/W&?#^GZW=:U^]!3&E$L"."`<?
M-^SQ\$/A3J?@GQQX<U#_`(55XDTWQ?X3L-0\:/XAOGUGXIRZDS^%K/P7\1-4
MUO4WD\?W6NSZO%!;/JKWUY'J+6D]D5N$4,`<)J/[6&O^']%LK;7=+\)V_C3P
MO\2?C;IGQ<L+:>=[;PY\*O@;H>N^-M9\;:9IIUIKF*[U?P==_"HVT=S=31V=
MQ\3K*6=)HXA!*`8_Q>\3?'S5_P!FCX[7_P`1?#7PXC\(>,_V5?C3XFM)O!6I
MZO'JWP^U*3X:376F^#M?&O7+KX\-W:ZCJK?\)!I-KHL<,FC^5)I@2ZCN*`,C
MXI_M2>,?@UX?U36]-N_AC?>%/A3X.\&ZAKO@=-*\;>,?B5XIL]1\,:'?SNVJ
M>$KQ-+^$K1->7`A/B'3=5BN(+9+R>:PM9_-C`V\K'N5Q\5?C!XG\6_%"/X5^
M&?!6J>%O@UXSTWP'K^C>)+G4+'Q;XYUX^%_"OC+Q$/#&M#5+71_"MKI^B>,M
M)CMI=6M[];ZZM[M)#80K'/(!MY'@DG[>>CKXO9X?%/P:;PY'\9U^#I^%C^(Y
M(_CW)"?B$OPR?Q]%I?\`:_V?["-;8ZNN@MI(N&T)/MYODE;[,@![[^R7_P`B
M=\5_^SI?VI__`%>WCB@#\Y?A;\,8_&7PKO%^&'[,_BG3OCIJ7Q=^*S:%^U3;
M+\//#WA_2+O3OVA_&,Z:]?>([3XB6_C'5M+TC2+%=+N=(?P^5U`:7)IXCELY
M4G<`^B8OB-\4/A$?VX/BEX9M/`U[X%^'/[0&I>+/%FC:Y:Z[<>*O%%G9?`[X
M+/KFD^'+^PU6RL?"UU;:=#87%O>WMKK:74MQ-;O;6BQ+<R`;>1Z1\3OVH?&/
M@/QIJRV=Q\*M5\*^'?BEX!^&FH^#-,3QAXE\?2Q^./$?@;P\VO:UXOT-AX;^
M'.HV;>++J[3P]K-C=2W,%M8C[?!<:C%;4!MY6,[XA_M&_'?P_9?'W7_"6@?"
MF\T3X1_'3X<?!WP[IVOKXLM]4\2W'CV]^`%NQU74-/U1H-'%JGQ2US_B80VE
MT"9M.;^SV&E7"ZV!MY%CQI\?/V@?!D_[1&GRZ7\'[^7]G;X5Z/\`&C4]4CL_
M&=K!XN\/ZUI7CG5X/!FGZ.VMROH.LQ1?#KQ#"VOS:AJ$#M<V+_V0@>58P"Q\
M=/VH?&7P[M?%&N>&+CX516'@7X6:?\4-1\&ZROC#QAX_\40WFAZ_K4FD"T\%
MF"+X8:=C2K:&V\1:[;ZG;7+&^EDM;6VLFN&`.ZU'XO?&/QCXC\:V'P3\._#J
M^M/A;HGA*^\2:1XVU+68=:\9^*/%W@Z/QQ:^!=`U33)[>Q\#M!H&J>&9/^$@
MU2#6H9IM;:)M/MXK5KIP#PGQG^WMI?ACQ+XXO&\9_`'1O#/PT\<R^!]?^&GB
M3QL\7QI\2#1]0T?2?&GB#0Q:ZDMAH[Z-J4WB.&TT:72M5;65\/"5-0T];R,*
M`>N^,/VBO&WA[X4_MF>.K+2_"TFK?L[>+_%.@>"K:YL=6?3M4L]$^%/PW\=6
MDOBF&+6XYKVY?5O&&IPR-87&FH;:"U1425))I@#PK6O%OQ)T[XK?':'QI?>"
MO'OA+3?VTOV1_"OA/PWJ^B>,%3P<OBUO@==:1JOA]G\?RVMC?:3I.OVM_LBL
MX[:X\36U[K3VXM;_`/LJW`/I?X7?%3XS_$5/!OQ*L_#OPYN_@G\0;_4#I5GI
MVJ:I:^/?"_A".+Q!)X=\>:KK&I7:Z/XF76#IVB>=X?L-.T^?3%U_<M_J8LY<
M@'G7@']J+QEJOQ;^%G@WQ#=_#+Q!H7QGO?&&FZ';_#;2?&]ZO@2]\'^#=>\8
MSQZO\4[Z[G\*_$);J#0+JT5=)M-$F21_,BAN[>">6$`\$^!GQ]\??#KX&_LZ
M>&;&S\#>$O"5A^S]\,/$5IXK^)^G>,X/#/Q"U+4UUC3M8\&Z5\1-$$?AWX9:
MOI/V/P_,;GQ$=1DO!XB46VG^5:S7"@'ZTQN)(XY%*E9$5U*,KJ0RA@5=>'7!
MX8<$<B@#\VOB-\2O%?PC^,W[8/CCP/I.A:[XHM?#O[!7A[2M'\2SWUIHM\?'
M7Q6^(/@6[@N[W33]HTYS8>)+IH;Q([E;>=89Y+6[CB>VG`/2?%7[1OQ+^&?B
MSQC\.?%VA^!O$GC`Z;\#KOX<7OAE=?\`#V@W&J?'GXH^(?A)H6B>+8-6OM4N
M8[;1]>T(ZA=:K93(;JRG*Q6%O.@60`^DOAY>_%7[1XBTCXHZ=X1,VER:9-H/
MBKP4;RPT;Q)9:A#<M=P2>&=7U?4M3T'4=,NK;R9&GO+B"Z2Z@FMY`PG@M@-O
M(]-H`*`/G'X2PKH/Q<_:!\,2`1277B'PYXVL@"$2ZL_$VDR/=SPQYW%H=0@>
M*9R`#(ZXX(S]QQ))XOAK@O'QUC3PV)P,^\)X6LE",GM[U.2E!?RI]C\XX2@L
M!Q=X@99)*G*IB\'F5-;*=/&X=NI*,=[PJP<*CZR:[G)>"O!NHP^`OCM\((4@
MAU_0_%>OZMX616C\I['Q%!!XG\`ZA*TBF,*^J6DD4H"[8VL)H\[HV(]+-<TH
M?VQPAQ+)R>"Q>$P]'%[W53#2EA<QII)IW5*:E!WO)5(RM:21Y.29-B(9!QWP
M?!1IX_`X[%5\"E;E=+%QCC<JJMM<J3KTW&:M:,J4X7YHMGHLVJZ+XB;3?%EO
M).GA?XK^#[3P+J.J6Z[GT'6X[_4T\-6FH<YT^X_M3Q+XDTEV=$,6J+96DH\V
M=!%XD,-BL`J^6SC'^T.',;/'TJ,G95Z#ITGBIT_^?D?987"XE)-J>$=6M#W(
M2<OHIXK!9B\-FU.4HY7Q7E]/+*M>"N\+B55K+!TZO6E/V^,QF$DW&+AC50P\
MUSU(J/K.A:M+?0FUU&`6&O6$5N-8T[*8CDF$J17UF4ED%QH]X]O<O:SAB2(I
M89A%=6US!;_-XO#1H252A+VN#JN7L*FJNE9NG.ZCRUJ:E%586T<HS@YTJE*I
M/ZW`XJ=>#I8B'U?'X>,/K%'3W7+F2JT[2ES8>LX3=&I>[494ZBA7I5J5/=KD
M.XJVE[9WT;S6-W;7<,5S=V<DMI/%<1QWEA=365_:N\+,J7-M>V\]O-$2&CEA
MDC<!T8#2I2JT)*-6G*C)QA-*<7!N%2"J4YI-)\M2$HSA+:4)*46TTS*E6HUH
MN="K"K"$ZE-RIRC)1J4IRI58-Q;2G3J0E3J1?O0G&4))232M5F:A0!^37QNN
MI?V,OVT+_P#:[U_2O$>K?`?XX^!=)^'GQ6UG1;)-9F^'?C;21X?TOPSK5UID
M'E7$?A^YTSPQHT(D1KAC->:LJI)</I]K<`?@?6=E^W7^R%J$6FR6/Q^^']R^
MK7%M:Z?8PZA<MJTUS=O%';P/HOV3[?;2O)-&@6:VC.XE3@J0`#L_VK=%TC7O
MV9?C]I^MZ7I^KV*_![XBZ@EGJ5I!>V\>H:1X4U75=)OXX;B-ECO;+5+.SO+:
M=0)(+BTAFB9)(D90#A?V"]-T_2OV._V>X--L;73X;CX<Z1J4\5I!';I-J&JF
M;4=2OI5B51)=75]<W%Q+*V6DDF=V)+$T`?&/P5^+UG^P9\6?C%\!_P!HF'4/
M!GPH^('Q0\7?%'X#_%V[T[4;_P`)ZM9>))[6;5/"6IZOI]M(EKJ=C;_V2\@:
M!/(NI+]KIHK:]TV2Y`/T&\#_`+57[.OQ+\5Z=X&^'OQ?\&^,?%>JVUY>6.B^
M'-0?5+F2UL+-[^\FE>TA>&T6&UC=F^T21$,!'CS"%(!\"_L;_M'_``(^#\_[
M6_AGXH?%;P7X%U^^_;9^/6NV>D^(]8@T^^N-'N7\+Z?;ZC%#+RUK)>Z9J$*O
MT+V<H_AH`]-_;=^*]E\7?V>_`GPR^`?B_0_$.K?M;^/K#X5>$?$>F7AGT1O#
MEAJT[?$36)M0MT?;HUA%H\VEZ@88;F?RM1N$A@>0;HP#@[O]D']N"\^##?`"
M;]H'X%_\*P/@:'X>KH:_":198O#UOIL>F6YCOO(\Y=5B2**X6_W&<74:W)<S
M?-0!Y9X'\)>*OVB_^"??QI_8\ENHK_X_?LS^()_`$NEW4YB>\_X0+QG+K?@-
M;":5D@&F:MX=T+4_#&FSS2+$&TKSI2D(69@#ZK^!O_!0OX,ZQX-TKP_\?/&>
MG_!GXZ^%;2W\/_%'P9\0K*[\'S6WBW3+<6^J:EI[7MK'9#3=1GADO8;9+AI;
M9+M()5R(WG`.<_;A^,'PS^-'[`?[1?B/X5^,=(\;Z#HUWX6\,ZAJVB//+80:
MY:>.?AUJES81W,L,:7+)8:QILQD@,D1%T%#EE=5`.?\`@3XY_P"":FF^"?@W
M-*/V4;+XF6'A;X>227Q\'_#^'QA:>.K72=(9[LZD-#%[%XEBU^,R?:1,+A;I
M/,W^8-U`'G7[1_C[P9\,?^"L7[._C+X@>)=)\(>%=+_9PU*/4->URZ2RTVSD
MU"X^/.GV2SW+_+&9[ZYMX$SU>95ZF@#]+OAO^T?\"/C!KEUX9^%_Q6\%^.=?
ML=*GUV\TGPYK$&H7UOH]M>6.GW&HRPQ<K:QWNIZ?"S]`]W$/XJ`/;*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@#%\2>'-"\7^']:\*>)]*L];\.>(M+OM%US1]0B$UEJ6E:E;R6E]97
M,1QNBFMY9$.""-V5((!`!X7X>_9H\.:/K7A?4M:^('Q:\?Z1X"U"PU?P!X-\
M>^+;36?#'A#5]+TVZTG3M5@^RZ'9ZMXIU*UM+R=K>X\6:MXADMIRES;-#<1K
M*H!Q?PW^#D6L_'[X_?&SQ3\/+[PG:>-=#T3X7:+HWB:3P]=7OB+3=+LQ9>.?
M'(@\.Z_JUO9:3XJM--\#Z7%%<26E_-:>`+26^MH@]O'"!M\C:;]D?P%<Z%XD
M\.:SXQ^*GB/3=6^&'C3X.^&T\1^+K;59/AMX!\>Z'8Z!X@TWP4T^B@7&HO8Z
M9IWEZQXF7Q'J(^QK&]U);O+!*!M\AOB?]D+X=>*=)^('AFY\3_$S2O!_Q2M[
M5O'?A#0/%=OH^CZ]K=GX;T+PI%XFGN;;1_[5M]2?1?#.@PSV,&I1:/=_V<!=
MZ7.D]PEP!^!N^(OV8_!'B:[UF35/$/CK^RO&2:(WQ1\+VFL:59>&OBU>Z'I6
MFZ'#J?CS3K?059[R\TG2--L[]=%FT:"_M[.*WNX9;=!$`/P-/3OV>_#&C>(E
MU/1_%?Q"T?PHOB74?&A^%>E^(;73_AT_BW5M<;Q-?ZVUE:Z0FL+'-X@GO-0D
MTA-;31Y9[^X>;3I"XV`'>?#SX=:)\,]-\0Z5H-UJMW;^)/'WC[XBWSZM/:3S
M1:W\1O%FJ^,=;M;1K.QM532H-3UBYBM8Y$EF2!(EFGGD5I7`(OA9\--"^$7@
MRV\#>&[O5KW2;37?&?B".XUN>SN=1-YXY\:>(/'6K1/+86%G#]EBU?Q)?0VR
MBW#I;10)*\TJO-*!M\CAM=_9U\$Z_P""_CUX%O-4\4Q:1^T1KFL:_P"-;BUO
M=)CU'2[S7/!?A3P+=Q>%I9=#DAL;9=)\'Z9-&M_;ZDXN9[IV=XGCAA`.7\4_
MLG>"?$]IXQTC_A-/B=X>\,^,/%R_$1_"?AO7M#L-"T+XD#Q-%XTE\=:.ESX8
MN;RYU67Q?!;:R^GZS>:MHIO+=)1I:DN'`.DU#]G+P5J>@?$7P]=ZSXM:U^)W
MQ<\%_&CQ#=+>Z*E]!XK\#7/PONM+M-+8:!Y-OH=Q+\)O#INH)H+B=Q?:D(;F
M#SK?[&`:7BKX">#_`!=<?'&XU+4O$MN_Q^^%ND?"3QB+&\TN)-,\-Z-IOC_2
M[6]\,B?1YC9:V]O\1M;:2:^.HP%[6Q*VRK',MR!L<OXD_9:\"^)6\96TOB3X
M@:/X?^)/A:S\+?$KPKX?U[3M*T;Q[#I_A>Q\%V&K:Y<QZ&VKVNK1>%=-L],<
M:1JFF6EU;PK'>6ER`,`$.L?LL>$];LH]/N_'WQ9MK?4O!NB>`OB(NE>*M.T8
M?%OPWH.EWVC64'CJ/2_#T$=GJ$FGZE=PSZEX43PS>3Q-';R3M:V\,$0!KR?L
MV^$8]>N[_2/%GQ*\,^%]4UNU\3:[\,?#7BTZ1X`UKQ!:2Z3.NHSVL.GG6-+B
MGFT:T>]TW1]:TW3=1::\;4;*Z:_N3.!^!SOQ%_9'\!?$BT^+&D7_`(O^*'AW
MPU\:I!J/C[PKX3\46.E:)J/B5-%T7P_'XJMS<:%=7UKJ?]F>'-!CELA>MI-V
M-,C%]IMRDDR3`?@;WB#]FCP9X@\9^(_&<_B+QO8R>*O'_P`(/BAK/A^PU'0Q
MX=F\;?!:^\+W/AC68H;WPY<W]L;S3_!OAW2]1MX]06"6TL2UM':7DTMW(`,T
MS]F+P'IVOZ?J,FN>/=3\,:#K6M>)?"?PQU7Q.;CX>>$O$7B*#Q%:ZQJVC:;%
M8Q:E,9+?Q5KD=M8:GJVH:?IJWB_V79V1AB,8!E^'OV4O!GAG4/A-?6?C?XJ7
M4?P,O2_PKTO4/%&G3:+X4T%_#5YX.F\)+I4.@10:WI#^%KZ;3!?ZPNH:W#`6
M%MJT+33-,`8$'[%_P\LO!^C^`-.\<_%S3?!MO\.='^%/BWP]8^+-+@T[XE^"
M=%L-5TRVT[QE!_PC1%G>2Z?K6H6]QJ'A?_A&[N>*5(Y)S'!$L8![KX9\$:EX
M=\?^-_$H\0:O-X8\0>'/AYH/A[P;<:WJ%_H7AF?P:GBF/4]5T32+B)+;P_-J
M]OKND6]U':F8W'_",VUQ-*6=8K<#8XCQ?^S?X'\::[\0_$&J:KXKM[SXER_`
MJ;78M/OM(BM;1OV??'%UX^\&#2$N-"G>W6]UB[DAU/[1)=>=;*J6ALI09F`V
M-+QI^S_X"\?>*?%'BWQ&VN3ZAXI\$^!/!,T%KJ$-C;:,GPV\:^(_B#X/\3>'
MY[:R6^TSQ98>*?$DUVE[]LDB4Z98[+=3',UR`5]#^`FEZ!<76L6WQ`^)MSXO
MU;Q-X*U[Q/XZO-:T%O%'BO2O`=U=W&B>`M;>W\,0Z='X!:+4=5@GTS3M.T^1
MUU>^F2XCN[J2Y8`]WH`*`/FWXL_;_A[\0/!?QFL4E'AR.W;P/\4_*$;K%X7U
M&]CDT'7)8&&X1:7K=S)+-/"&F\J1(Q^Y:4'[KAOV.<Y+FO"U5I8Z4EC\IO=7
MQ=.#6(P\9+2^(H1480E:'.G+X^4_-^+/;\.\09+QG0BUEL8/+,\Y;-1P56HG
MA<3*+UY<+B9N52<+U.1QA_#<T=5X^L]6\*>)=*^*WAZ#[7I]EIKZ-\2=)ME>
M2\U3P=#)+>V6M:;!&I^U:KH%U<7MTL2_O)[2\O((]TAB0^=DU7#8_`8CAW&S
M]C6JU57RNM)J,*.-:5.I0JR;7)1QD(PIN3]VG6A2J2M'G9ZN?T<7E6987BK+
MZ?M</0HO#YQ0@FZE;+XN52EB:,8KWZ^`G.I54%[]6A4K4X7FX1%.GV>BK=ZO
MX?TF+Q-\+O&]JNM:QI6B(+V33[W4U%S/XIT'38<MJFDZI:S17%W9Z?FX%Q`+
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M92B1E<QWJ'QI*9X=WRRE[>X)3>H616V/S1E&.O\`:."IZWO#"34XVTO!K`QY
M9=8VG!*5FW%JZZY0E;E_LG,9)*R4\=3]F[V;51?VC/FC?2?-3J-QO%1G%\KJ
MR>(1X3N+2'Q)>:?:76L+_9W@[P!X7A.H75S_`&=;)+=?8"UC:W6HSKG,L_D:
M?I]A;-#]HV!7NY-(X'^T(5)8"E4G3PC]KC<PQ4O90A[634/:6J5*=*+^S#GK
M8G$5>;V?,W&C'*68?V34I0S&M2HU<6O8Y?E6"C[6<_904I^RO2I5:TEO.?L\
M/A,+1</:\J4J\O2!T'&/8XX]N*\,^D"@""YMK:\MI[.\MX+JTNH9;>YM;F*.
M>VN+>=&CF@G@E5DFADC9E9'4JRL000:`/);+]GCX`:9J_P#PD&F_`WX/:?KW
MG"Y.MV7PS\%6FK_:`_F"?^TH-$2X\X2?-O\`,W9YSF@#U/4],TW6M-U#1M9T
M^RU;2-6L;O3-5TK4[6"^T[4]-OX)+6^T_4+&ZC>&\LKBUEEAE@F1XY(Y&1U*
ML00"OH6@Z'X6T?3O#OAG1M*\.Z!H]K%8:1H>AZ?::3H^E6,`VPV>G:;80Q6]
MC:QKPL4,:(HX`%`;>5BOXC\+>&/&&F2:)XN\.:#XIT:9M\ND^(](T_6],E<)
M)$&DL-3MYH';RY94R8R=LC#HQR`<EX0^"WP=^'FH-JW@'X3?#3P-JCQS1/J7
MA#P)X6\,Z@T4YS/&UYHNE6TS1R'[ZE\-W!H#;RL<OJG[+_[-6MZEJ.LZS^SU
M\#]6UC5[Z[U35M5U/X4>!+_4M3U*_N)+N^U#4+ZZT%YKR^N+J66:6>9WDDDD
M=W8LQ)`.OT?X0_"?PZW@]M`^&'P]T-OAW_;O_"`'2/!GAS33X&_X2EIG\3?\
M(@;/38_^$:_M=[BX:^_L[[-]K,\AN/,+G(!Z)0!R.C?#_P`">'/$7B#Q=X?\
M%>$]"\5^+6A;Q5XFT?P[I&F>(/$K6Y)MVU_6;*SCN]8:,LQ0W<TVW<=N,T`8
MWC#X.?"+XA72WOC_`.%?PX\<7L:)&EWXP\#^&/$UTD<94QQK<:UI=S(J*40A
M0P`V+CH*`)Q\)OA8O@^^^'B_#3P`G@#4Y$FU+P.O@[PZOA#4)HY[2Y26^\-+
MIPTZZE6XL+&4-+;,0]G`P.Z)"H!P=O\`LJ?LOV=Q!=VG[.'P'M;JUFBN+:YM
M_A%X`@N+>X@=9(9X)H_#ZO#-'(JLKJ0RLH(((H`ZOQM\#_@M\2]5M]=^(WPB
M^&/C[6[33XM)M=8\:>`O"WBG5+;2H+F[O(-,M]0US2KF>'3X[N_OITMTD$:R
M7D[A0TKE@`\$_`_X+?#/5;C7?AS\(OACX`UN[T^72;K6/!7@+PMX6U2YTJ>Y
MM+R?3+C4-#TJVGFT^2[L+&=[=Y#&TEG`Y4M$A4`]1H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,_
M5=*T[6M,O]&U:TAOM+U.SN+"_LKA=T-S:7<30W$$B@@[7C=AD$$9R""`:VP^
M(KX.O1Q6%J2H8C#3C4ISCI*$X-2C)>::OV?6Z.?%87#XW#5\%BZ,:^%Q5.=*
MK3FKQG3J1<9Q:[23:TLUNFF?/OAG7K_X)WUKX`^(NL75]X/U354T[X8>.;V-
MI8;>WG$@L_`_BR^'-KJMK#$/LMY.!#=0"0^9$+8PP_:8_!T>*:-3.<CPL*&9
MX:BZN:X"FU%RE&W/C\'3^W1J2?[ZE!\]*HX^[/VBG/\`/LLQ]?@BO1X?XBQD
MZ^3XJNJ.2YG43<80E?V>68^K]BO2C']Q6FO9UJ?-[T%3=.'9/X*U_P`#7RW_
M`,+1I:>'[B>ZNM>^'6IS36>E33W#K*]_X,OXTD7PMJ3R&9I+)H7TVY:0'R[.
M5Y+IO+CFN"S6BZ'$'M?KM.,(8?,J48SJQC%-*GC:;<7BZ27*HU5)8JDE;FKP
M4:2]IY+C\CKJOPLJ$<OJ2J3Q645I2IT)2FU)U<NJQ4E@:S?,YT7"6#K2=^3#
MS<Z[Q-1\2_#'3)VO_%NG>(?A1J5U=*]W<WIUKP=::A>R$HKZAXE\'ZB=!UZ;
M=N^6?4KM@`'9`A5CUT,!G]:"H997PW$-"E"T(4_88V=."U:IX7&TUC,-'SA0
MI)MV3<KI<.(S+AC"S=?-L-B^$\14FG4G4^LY=3K5'HG5QF7U?J&*E>^E3$UF
ME:3BHM-P7'C;X-PQ&6\^/%K=6D:'-I;_`!/TR*4H4D#`/H%U!J4CG>6!$S.&
M50I4`"KAE/%#ERT>#YTJC?QRRJJU>ZMIB(3H):6^!1:;O>[9G4SO@V$.:MQY
M3JT8K^'#.J,96:=]<).GB6W>^DW)-+EM9(TM#\1^'8_,NOA?X#\0>*KW4H8Q
M)XGN;.\T73[R$MYD$NH^-_&YBO\`6].!?S!)ID>MD>:62)B7V\^+P.-]VEG^
M<8;+:5"3MA(3A7J4Y;25+`8#FHT*KM9QKO"7M:4E[M^K`YCET.:KPOD.+S6M
MB8I/&SIU,-2J1O>,JV99ER5\31UYE+#1QS7->,&^:W<>&-.U_1+/4=9\<^*8
M]2U*YB:ZOX[=8=,\(^&[*U:YN/LNC0/&DPM88)3Y^H:E//<3^0'9H8E2"'R<
M?7P6)JT,)E&7/#T*;Y*;DY5<9B9SY8\]>2;CSRDOW=&A"%.'-RI3FY5)>WEF
M&Q^!HXC&9YFBQ&)J1<ZJ@HT,!@Z<'.?)AXM1GR0C+][B,3.I5J\O,W3@HTH=
M7INHV.KZ=8:MIES%>:;JEE:ZCI]Y`=T-U97L"7-K<PL0-T4L$L;J<#(85YU>
MA5PM>MAJ]-T:^&G.G4A+24*D).,XM='&2:?FCUL-B*&,P^'Q>%JQK8;%4X5:
M-2.L9TZD5.$XO^649*2\F7:R-@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`,W5]&TK7],O-&UO3K/5=)OX3!>Z??P1W-I<1$AMLL,
MJE20ZJRMC*LBLI#*"-\+BL1@J]+%8.O/#8BA+FIU*<G"<'M=25GJFTULTVG=
M-HYL9@\)C\-6P6-P]/%83$1Y:E&K%3ISB];2C)-:-)I[II23329XXO@WXD^`
M+RW;X<ZY;>*O!L:XNO`GC[5-0DU/3DC$FV/PAXU:*ZN88C&+:**QUA+J"(0/
MLG03#R/I_P"T\BSBE-9WA)9;FE_<Q^74J<:51NUWC,"G3IMWYY2K85TZDW)<
MU.3C[_QRR;B3A^M3?#F.AFF317OY7FM>LZU%*]EE^9<M6I&-N2,*&,C5I047
MRU8J:]GOCXI)9*8_%7@#XC^&9%0F<CPI<^,=/7$222,M_P##Z378_L^'8!YU
M@/[MMR(?EKC_`-7G4:>79SEF.C?W5]<C@JFK:5Z>8K!RYM%I!S6JM)K4[UQ1
M&BG'-<@SC*Y)/F_V&>84E:*;:JY2\?'DU=I35-Z/FC%Z',6_QI^!J7<(L9W;
M43-Y<$-C\-_&3ZD;A\J8X[>V\)FX$^2P*A0PY![UZ$^%>+?9R]K!1H)7DZF9
MX)4E%:W<I8Q0Y>J=[/='F4^-.!HU8*A4?UARM&-+)\Q=;G>EE"&`=3FW35K[
MIF\_Q.U_4@8_!WPH\>:M+D@77B6UL_A[I,7+('GD\3SQ:F4W[2?LVD7+;&+!
M6(VGCCD&"P^N9<19?A8K[&%G/,:SZVBL)&6'O:Z]_$TUS:-I.YWOB;'XA<N3
M\*9IBY=)XR%/*:$=U>3QLXXJU[-^SP=5\K;2;7*\JQ^&'B7Q:[7GQJU^P\26
MPDCFL?`'AN*\TWP+82*[2;M4$KI>>,9580B,:F%MX_+9A;,TFY.BKG^`RM*E
MPI@ZF`J6<:F8XEPJ9A435K4N5.E@D_>YOJ]ZDKI>U25GR4.&,SS:3K<:X^EF
M--24J658.-2CE=)IWO7YG&MF$D^7D^LVHQLVJ+E*\?<(HHH(HX88TAAA1(HH
MHD6.***-0D<<<:`*B*H`"@````<"ODI2E*4I2DY2DVVV[MMZMMO5MO5M[GW$
M8QA&,(14(02C&,4DHI*R22T22T26B1)2*"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!CQHZ-%(BO&ZE'C=0R,C##*R,,,I!(
M((P<TTW%IQ;BXNZ:T:?=-;,3C&47&24HR5FFKII[IK9I]CF8?`W@FVN4O+?P
M=X6M[R.7SH[J'P]I,5S'-DMYJ3I:!TEW$G<&!R>M=\LWS6=-TIYGBY4FN5P>
M)K./+V<7.UO*UCS(9%DE*I&M3R?`TZT)<RG'"4(SC+?F4E34E*^MT[G4UYYZ
M@4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'CWQUO[[3
M/AUJ-QIUY=6%Q]NTR+S[.XFM9O+ENT66/S8'5MCKPRYP0<'B@#E?AS<2-X^N
M(?"-QKESX$7PQ;MJ9U.;6;C3H?$1="1ILNM$RB=D*[@C$,#,>52/:`?1=`!0
M!\3W^IBXU'XGHVM^(CXWB\<7.F^`[:PU;6Q='R]:N(GLK2TM[C[,;1+<(K"5
M,1H%"%<@,`?8NB_VB-'TD:QL_M8:;8?VIY>TQ_VB+6+[;L*?+L^T^;C;QC&.
M*`-.@#Y_^/U[<66G^#A#<ZG;PS^*(8+Q-)GN8+RXM7@;S8(A:NKR2,N0B`Y+
M%<<T`>I>!X=/A\/6QTN#Q!:VDDUU(L'B<WW]L1OY[Q/YZZB[S1QLT6Z,,<%&
M5APU`'74`>??%%?$Q\#:VOA$W(UGRH/+^PEEO_LOVF+[<+$I\PNC:>;CR\28
MW>5^\V4`<[\'=3\+7VE7R>'[K7EO[8V4>NZ5XAO[V[N].OECEC>2)+J5TCCG
MF6XW-#M#&$!TC9`B@?@>QT`5;W[5]CNQ8F,7OV:?[&9?]4+KRG^SF3C_`%?F
M[,^V:`/G#X/ZC8IKKZ7XIN?%=G\2U_M0WUKK>HW_`/9^K0O+),KV=FTQMV,%
MF@95V`$1R2PL\8'E`'TS0`4`%`!0`4`?$E_J6H76M?$&+3=9\12>/8_B'/I_
M@JTLM4U4DV-MJM\;^T^R^?\`8QIL%C&I83($C6.->(BP(!]J6WG_`&>W^U;/
MM/DQ?:/*SY?G^6OG>7GG9YF['MB@">@#Y_\`C]>W%EI_@X0W.IV\,_BB&"\3
M29[F"\N+5X&\V"(6KJ\DC+D(@.2Q7'-`'KGA"*R@\.:9'IT6LV]GY<\D$/B$
MW9UB,374\SK??;G:</YDC[5D8X38!\H`H`Z2@#S#XRW-S9?#3Q/<6=Q/:7$4
M6FF*>VED@FC+:SIR,4EB963*,RG!&0Q'0T`=5X,DDF\'^%)II'EEE\-:%)++
M(S/))(^EVK/)([$EW9B26)))))H`Z6@#`\62/%X6\2RQ.\<D>@:S)')&Q1XW
M33KED='4@HZL`00001D4`>'_``$>TO=.M=0F'C";7CI^HK>ZCJDVJR^&[J$Z
MP\<2Z=+<S-:S7<<,5LC>6H93%.">&R`?1]`!0!\GZ]XJUB'XB2^.8M0ND\(^
M'/&6F>`KBT2>8631R6%XFM7DT"N(I#!<S2.K%3S)#SPIH`^L*`"@#Q'XV2:]
M!IOA^XL8]9E\-6VKB;QC#X?FDM]3DTM/)90LD#+(MKL%WO.Y4#F$NR@!E`.X
M^'M[X=OO"UC/X6OK^^TD27*Q/J=U=75_;RM.\DUG<O>.TJ-"9`BH6(";"I96
M#L`=M0!P'Q3GGM?A[XKN+6:6VGBTJ1HIX)'AFC;S8ANCDC(9&P3R".M`''_!
M/[!/HBWL4?BX:G)I>D_VI=>(9-4;3;V>=+B0SZ&U]*T4T.^)RSP``+)%GAA0
M'X'M]`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!P_Q#\'-XY\,7/AU-072S
M/<V=P+MK8W83[+,LQ7R!/#G=C&=XQG.#0!V5O%Y%O!!NW>3#%%NQMW>6BINQ
MDXSC.,F@":@`H`\'O?@E'>1^+'.O>1J>M^+O^$NT34X-/:.?0+LW=U<&$8O0
MUVIBNBA97@^>*.3;F-0`#VZR2ZAL[6*^GCN;V*WA2ZN883;17%PL:K-/';F2
M3R$DD#,(][[=V-QQD@;>5BU0!YQ\1?`ESXWM]#2SUB/1;C0]7CU>&>2P_M!7
MEA0B)##]J@``?:QR6!QC'-`'7:#::U9:>L&O:M!K.H++*S7MMIR:7$8F(\N,
M6D<\H4J,@MO^;/04`;-`&-K]GK%]I<]KH.L)H.IL\#P:D^GPZFD(BGCEEC:T
MGD1'6:-&B+$DJ)"RC<!@`X_P'\/Y/"-YK^MZGK+Z]XA\2W$<^I7XLHM.MT6)
MI76*WM(7<)EYF+-N`(2,*B;3O`/2:`(ITED@FCAE\B9XI$BG*"7R960K'+Y9
M91)L8AMI(SC&1F@#R?1/AMK$?B^R\9^+O%G_``DNIZ/8RZ?I"6^C6NC0P1S)
M<Q/-<);2NLTA2\NB%"KAI<[R%55`/7:`"@`H`*`"@#P6[^"DDMQKVHVOB7[#
MK-_XU/C+1M1BTPE]'D>XNYI;&1#?#[9&ZW,>6#0Y:UC)4KE2`>[1"411B=D>
M81H)GB1HXVE"CS&CC9W*(7R0I=B`0"3C)`)*`/./B+X$N?&]OH:6>L1Z+<:'
MJ\>KPSR6']H*\L*$1(8?M4``#[6.2P.,8YH`[/1;?5;/3+:WUK48=6U./SOM
M.H06*Z;%<;[B5X=EDDL@AV6[11G#MN,9?C=@`;?(U*`.3\<^&6\8^%=6\-+>
M#3CJ26JB[:W-R(/L]]:WN3`)HM^[[/L_UBXWYYQ@@$7@O0=?\-Z8FEZSK]MK
MD%E;6%EI7V?2$THV=I96YMQ'*5NIC=.R+#\[%2/+/7=P!L=C0!FZQ8'5=(U7
M2Q*(#J6FWU@)BGF"$WEK+;B4Q[EWA/,W;=RYQC(SF@#@_AYX)\1>![2VT>Y\
M4VNK>'[&VO([/3X]"2PN(KF[OFOFN'OOMTSR*'FNAY97_ELO(V`$#;Y'IU`$
M<PE,4JP.L<QC<0R.AD1)2I$;O&&4NJO@E0RY`QD9S0!X0/@'X?;PC<:+<W"3
M^)KEIYY/%C07"S?:Y;\W2R_V?]O,97R-L#*9"6!=MP+<`'M.CVESI^DZ987E
MV+Z[LK"TM+B]$1@^US6\"0O=&$R2&-I60N5WM@L>30!I4`<EXLTGQ3JD%M'X
M7\41>&98S<+=M+H]MJRW<4R(D87[1(OV9X2'<,JMN+@'`'(!6\`>";/P!X=A
MT"SNI;T_:)KV\O)8U@-S>7"QI)(D"NX@C$4,**F]R!&"68DD@';4`<YXNT`^
M*/#6L>'ENA8G5;-K471A-P+?<Z/O,(EC\S[O3>O7K0!B^!?#'B+PI81:3JGB
M2UUO3+&QM;'2K>#14TN2T2W!3=+.MY.UT6CV#YMN"I.3F@#O:`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#D;[QWX4TR[GL+W5?(N
MK60Q3Q?8=2D\MP`2N^&S9&X(Y5B*`*G_``LGP5_T&O\`RG:M_P#(-`!_PLGP
M5_T&O_*=JW_R#0`?\+)\%?\`0:_\IVK?_(-`!_PLGP5_T&O_`"G:M_\`(-`!
M_P`+)\%?]!K_`,IVK?\`R#0`?\+)\%?]!K_RG:M_\@T`'_"R?!7_`$&O_*=J
MW_R#0`?\+)\%?]!K_P`IVK?_`"#0`?\`"R?!7_0:_P#*=JW_`,@T`'_"R?!7
M_0:_\IVK?_(-`!_PLGP5_P!!K_RG:M_\@T`'_"R?!7_0:_\`*=JW_P`@T`'_
M``LGP5_T&O\`RG:M_P#(-`!_PLGP5_T&O_*=JW_R#0`?\+)\%?\`0:_\IVK?
M_(-`!_PLGP5_T&O_`"G:M_\`(-`!_P`+)\%?]!K_`,IVK?\`R#0`?\+)\%?]
M!K_RG:M_\@T`'_"R?!7_`$&O_*=JW_R#0`?\+)\%?]!K_P`IVK?_`"#0`?\`
M"R?!7_0:_P#*=JW_`,@T`'_"R?!7_0:_\IVK?_(-`!_PLGP5_P!!K_RG:M_\
M@T`'_"R?!7_0:_\`*=JW_P`@T`'_``LGP5_T&O\`RG:M_P#(-`!_PLGP5_T&
MO_*=JW_R#0`?\+)\%?\`0:_\IVK?_(-`!_PLGP5_T&O_`"G:M_\`(-`!_P`+
M)\%?]!K_`,IVK?\`R#0`?\+)\%?]!K_RG:M_\@T`'_"R?!7_`$&O_*=JW_R#
M0`?\+)\%?]!K_P`IVK?_`"#0`?\`"R?!7_0:_P#*=JW_`,@T`'_"R?!7_0:_
M\IVK?_(-`!_PLGP5_P!!K_RG:M_\@T`'_"R?!7_0:_\`*=JW_P`@T`'_``LG
MP5_T&O\`RG:M_P#(-`!_PLGP5_T&O_*=JW_R#0`?\+)\%?\`0:_\IVK?_(-`
M!_PLGP5_T&O_`"G:M_\`(-`!_P`+)\%?]!K_`,IVK?\`R#0`?\+)\%?]!K_R
MG:M_\@T`'_"R?!7_`$&O_*=JW_R#0`?\+)\%?]!K_P`IVK?_`"#0`?\`"R?!
M7_0:_P#*=JW_`,@T`'_"R?!7_0:_\IVK?_(-`!_PLGP5_P!!K_RG:M_\@T`'
M_"R?!7_0:_\`*=JW_P`@T`'_``LGP5_T&O\`RG:M_P#(-`!_PLGP5_T&O_*=
MJW_R#0`?\+)\%?\`0:_\IVK?_(-`!_PLGP5_T&O_`"G:M_\`(-`!_P`+)\%?
M]!K_`,IVK?\`R#0`?\+)\%?]!K_RG:M_\@T`'_"R?!7_`$&O_*=JW_R#0`?\
M+)\%?]!K_P`IVK?_`"#0`?\`"R?!7_0:_P#*=JW_`,@T`'_"R?!7_0:_\IVK
M?_(-`!_PLGP5_P!!K_RG:M_\@T`'_"R?!7_0:_\`*=JW_P`@T`'_``LGP5_T
M&O\`RG:M_P#(-`!_PLGP5_T&O_*=JW_R#0`?\+)\%?\`0:_\IVK?_(-`!_PL
MGP5_T&O_`"G:M_\`(-`!_P`+)\%?]!K_`,IVK?\`R#0`?\+)\%?]!K_RG:M_
M\@T`'_"R?!7_`$&O_*=JW_R#0`?\+)\%?]!K_P`IVK?_`"#0`?\`"R?!7_0:
M_P#*=JW_`,@T`'_"R?!7_0:_\IVK?_(-`!_PLGP5_P!!K_RG:M_\@T`'_"R?
M!7_0:_\`*=JW_P`@T`'_``LGP5_T&O\`RG:M_P#(-`!_PLGP5_T&O_*=JW_R
M#0`?\+)\%?\`0:_\IVK?_(-`!_PLGP5_T&O_`"G:M_\`(-`'<T`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
;0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
